CCM

Business Context and Reporting Period

Company: Concord Medical Services Holdings Ltd (Concord Medical)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2009
Listing Status: American Depositary Shares (ADSs) listed on the New York Stock Exchange (NYSE) under symbol "CCM" since December 11, 2009.
Business Overview: Concord Medical operates the largest network of radiotherapy and diagnostic imaging centers in China. The company primarily enters into long-term lease and management services arrangements with hospitals, purchasing medical equipment and managing centers in exchange for a contracted percentage of the center's revenue net of specified operating expenses. As of December 31, 2009, the network comprised 88 centers across 57 hospitals in 36 cities.

Key Financial Metrics (Year Ended Dec 31, 2009)

Note: US$ amounts are translated at the rate of RMB 6.8259 to US$1.00. Net income attributable to ordinary shareholders in 2008 was significantly reduced by the accretion of Series A and Series B contingently redeemable convertible preferred shares.

Material Changes vs. Prior Period

• Revenue Growth: Total net revenues increased 70.2% to RMB 292.4 million in 2009 from RMB 171.8 million in 2008. This was driven by a 135.2% increase in patient cases from existing centers, the opening of 16 new centers, and the full-year consolidation of China Medstar (acquired in July 2008).
• Profitability: Operating income increased 64.4% to RMB 167.4 million. Net income increased 57.9% to RMB 124.8 million. However, gross margin decreased from 73.5% in 2008 to 70.1% in 2009 due to the ramp-up period of new centers and a higher mix of diagnostic imaging services which have lower margins.
• Liquidity: Cash balances surged to RMB 1.04 billion (US$ 152.0 million) from RMB 354.0 million in 2008, primarily due to net proceeds of US$ 120.3 million from the Initial Public Offering (IPO) in December 2009.
• Debt: Total borrowings increased slightly to RMB 149.9 million in 2009 from RMB 120.8 million in 2008. The company has secured credit facilities up to RMB 1.5 billion with China Construction Bank.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Guidance

• Capital Expenditures: The company estimates aggregate capital expenditures for 2010 to be between RMB 400 million and RMB 450 million (US$ 58.6 million to US$ 65.9 million), funded by IPO proceeds, operating cash flow, and bank loans.
• Expansion Strategy: Plans to continue expanding the network of radiotherapy and diagnostic imaging centers and to establish specialty cancer hospitals, including the Chang'an CMS International Cancer Center and the Beijing Proton Medical Center.

Material Risks and Contingencies

• Internal Control Weaknesses: The company identified two material weaknesses in internal control over financial reporting: (1) insufficient professionals with requisite U.S. GAAP and SEC reporting knowledge, and (2) significant advances made to hospitals without formal review of disbursement details. Remediation is in progress.
• Regulatory Compliance: Risks related to the conversion of cooperation agreements with non-profit hospitals to lease and management agreements. Some centers operate under interim permits or lack procurement licenses for large medical equipment, which could lead to fines or suspension of operations.
• Intellectual Property Litigation: A legal proceeding alleges a gamma knife system in the network infringes a third-party patent. The manufacturer has agreed to indemnify the company. Revenue from the affected center represented approximately 1.0% of total net revenues in 2009.
• Revenue Concentration: The top five hospital partners accounted for 33.6% of total net revenues in 2009. The largest single partner accounted for 10.1%.
• Taxation: Uncertainty regarding whether the company will be classified as a "resident enterprise" under PRC tax law, which could subject worldwide income to a 25% tax rate and dividends to withholding tax.

Unusual Items

• Share-Based Compensation: Included RMB 1.0 million in 2009 related to options granted in November 2009. In 2007 and 2008, significant share-based compensation expenses (RMB 49.5 million and RMB 4.2 million, respectively) impacted results.
• Accretion of Preferred Shares: In 2008, net income was significantly reduced by the accretion of Series A and Series B preferred shares. These were converted to ordinary shares upon the IPO in December 2009.

Key Facts for Investor Verification

• Internal Control Remediation: Verify the progress of remediation efforts for the identified material weaknesses in internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act.
• Regulatory Permits: Confirm the status of procurement licenses and interim permits for the 29 units of medical equipment that have not yet received full licenses, as these represent a significant portion of revenue.
• Revenue Concentration: Monitor the dependency on the top five hospital partners, which contributed over one-third of total revenues in 2009.
• Capital Expenditure Execution: Track the deployment of IPO proceeds against the estimated RMB 400-450 million capital expenditure plan for 2010, specifically regarding the establishment of specialty cancer hospitals.
• Intellectual Property Indemnification: Assess the financial strength and ability of the equipment manufacturer (Our Medical New Technology) to honor its indemnification agreement regarding the gamma knife patent infringement claim.